GlassScriptPhysician profile
Brittany D Jones
NPI 1801240924
$4,099.55
in general payments reported to CMS, 2019-2025
35 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $508 · 2021: $588 · 2022: $584 · 2023: $608 · 2024: $660 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,160.68 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $572.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $393.79 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $369.13 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $281.43 | 2023-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $193.08 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.65 | 2020-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $96.04 | 2022-2025 | Spravato |
| Glaxosmithkline, LLC. | $92.00 | 2019-2025 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.95 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.30 | 2021-2024 | Jardiance |
| Astellas Pharma US INC | $69.46 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $58.63 | 2019-2021 | |
| Abbott Laboratories | $55.99 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $53.11 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $51.40 | 2022 | |
| Allergan, INC. | $39.82 | 2021 | |
| Esperion Therapeutics, INC. | $33.77 | 2025 | Nexletol |
| Dexcom, INC. | $24.04 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $21.79 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $19.98 | 2019 | |
| Lundbeck LLC | $19.58 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $19.44 | 2025 | Sunosi |
| Antares Pharma, INC. | $17.35 | 2024 | Xyosted |
| Tandem Diabetes Care, INC. | $17.23 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Owp Pharmaceuticals, INC. | $16.78 | 2020 | |
| Vanda Pharmaceuticals INC. | $16.34 | 2024 | Fanapt, Hetlioz |
| Medline Industries LP | $15.73 | 2025 | |
| Amarin Pharma, INC. | $15.32 | 2019 | |
| Alkermes, INC. | $15.15 | 2025 | Lybalvi |
| Ardelyx, INC. | $13.64 | 2025 | Ibsrela |
| Eisai INC. | $13.61 | 2021 | |
| Sanofi Pasteur INC. | $13.51 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.74 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.